On May 25, 2023, Camac Partners, LLC filed a preliminary proxy statement soliciting proxies and recommending the shareholders of Forte Biosciences, Inc. to vote for the election of its 2 nominees, Michael G. Hacke and Chris McIntyre, and not to vote for the 2 Company nominees, Lawrence Eichenfield and Paul A. Wagner, at the Company?s 2023 annual shareholders meeting.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5831 USD | -1.77% | -1.80% | -29.04% |
05-30 | Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target | MT |
05-13 | Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-29.04% | 21.25M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- FBRX Stock
- News Forte Biosciences, Inc.
- Camac Partners Solicits Proxies from Shareholders of Forte Biosciences